The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Regeneron Announces Presentation at the 2011 Credit Suisse Annual Healthcare Conference

Monday, November 07, 2011

Regeneron Announces Presentation at the 2011 Credit Suisse Annual Healthcare Conference09:30 EST Monday, November 07, 2011TARRYTOWN, N.Y., Nov. 7, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the 2011 Credit Suisse Annual Healthcare Conference on Wednesday, November 9, 2011.  The presentation is scheduled for 9:30 a.m. Mountain Time (11:30 a.m. Eastern Time).  The session may be accessed through the Company's web site,, on the Investor Relations page.  An archived version of the presentation will be available after the live webcast through December 9, 2011.  Regeneron is a fully integrated biopharmaceutical company that discovers, develops, manufacturers, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, which is approved for the treatment of a rare inflammatory condition, Regeneron has completed Phase 3 clinical trials of rilonacept for a new indication and of product candidates EYLEA? (aflibercept injection; VEGF Trap-Eye) in diseases of the eye and ZALTRAP® (aflibercept; VEGF Trap) in colorectal cancer.  EYLEA is currently under review with U.S. and European regulatory authorities.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at Information:Michael Aberman, M.D.Peter DworkinInvestor RelationsCorporate Communications914.847.7799 914.847.7640michael.aberman@regeneron.competer.dworkin@regeneron.comSOURCE Regeneron Pharmaceuticals, Inc.